CYT387, a JAK-Specific Inhibitor Impedes Osteoclast Activity and Oophorectomy-Induced Osteoporosis
CYT387
ERK
ROS
osteoclast
osteoporosis
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
12
2021
accepted:
26
01
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
Osteoclasts are of hematopoietic lineage and have the ability to degrade mineralized bone tissues. Abnormalities in osteoclastic activity under certain pathological conditions are common in bone diseases such as osteoporosis, osteosclerosis, and arthritis. Although many kinds of drugs are currently used to treat osteoporosis, they have obvious adverse reactions and limitations. CYT387 is a new small-molecule Janus kinase (JAK) inhibitor involved in hematopoiesis, immune modulation, fertility, lactation, and embryonic development. However, it has remained unclear whether CYT387 functionally impacts osteoclast formation. Our study demonstrated through osteoclast formation assay
Identifiants
pubmed: 35345816
doi: 10.3389/fphar.2022.829862
pii: 829862
pmc: PMC8957263
doi:
Types de publication
Journal Article
Langues
eng
Pagination
829862Informations de copyright
Copyright © 2022 Li, Liang, Wu, Xu, Xiao, Yang, Sun, Zhao, Xu, Liu and Zhou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res. 2009 Apr 1;69(7):3196-204
pubmed: 19276363
Curr Drug Targets. 2017;18(9):1051-1068
pubmed: 28325144
Int J Mol Sci. 2020 May 16;21(10):
pubmed: 32429497
J Cell Physiol. 2021 Apr;236(4):2800-2816
pubmed: 32964459
Front Oncol. 2014 Apr 09;4:75
pubmed: 24782986
Circ Res. 2010 May 14;106(9):1489-97
pubmed: 20360249
Int J Nanomedicine. 2015 Sep 22;10:5941-54
pubmed: 26451104
Sci Adv. 2019 Aug 21;5(8):eaax1387
pubmed: 31457100
Oncogene. 2013 May 23;32(21):2601-13
pubmed: 22869151
Br J Pharmacol. 2010 Apr;159(8):1681-92
pubmed: 20397300
Exp Biol Med (Maywood). 2015 Dec;240(12):1690-7
pubmed: 25769316
Front Pharmacol. 2016 Jan 07;6:291
pubmed: 26779017
Cell Death Differ. 2018 Feb;25(2):268-281
pubmed: 28937683
Biol Chem. 2017 Sep 26;398(10):1095-1108
pubmed: 28384098
Oxid Med Cell Longev. 2016;2016:4350965
pubmed: 26998193
J Bone Miner Res. 2005 Aug;20(8):1462-71
pubmed: 16007343
Theranostics. 2012;2(11):1054-63
pubmed: 23227122
Immunity. 2017 Jul 18;47(1):66-79.e5
pubmed: 28723554
Biomaterials. 2019 Apr;198:107-121
pubmed: 29903640
Oncogene. 2016 Mar 3;35(9):1170-9
pubmed: 26028036
J Autoimmun. 2017 Apr 4;:
pubmed: 28389038
Int J Mol Sci. 2018 Oct 01;19(10):
pubmed: 30275408
Sci Rep. 2018 Jul 17;8(1):10797
pubmed: 30018287
Nat Rev Endocrinol. 2016 Sep;12(9):518-32
pubmed: 27312863
Endocr Rev. 2008 Apr;29(2):155-92
pubmed: 18057140
Oncogene. 2020 Jan;39(1):204-218
pubmed: 31467432
Brain. 2019 Apr 1;142(4):885-902
pubmed: 30805583
Development. 2014 Nov;141(22):4206-18
pubmed: 25371358
Bone. 2019 Oct;127:376-385
pubmed: 31299383
J Bone Miner Res. 2020 Aug;35(8):1582-1596
pubmed: 32286705
J Leukoc Biol. 2011 Nov;90(5):883-95
pubmed: 21807741
Front Endocrinol (Lausanne). 2019 Jan 08;9:788
pubmed: 30671025
Chem Rev. 2018 Sep 26;118(18):8798-8888
pubmed: 30148624
PLoS One. 2012;7(4):e34132
pubmed: 22509274
J Dent Res. 2015 May;94(5):674-81
pubmed: 25731711
Am J Transl Res. 2016 May 15;8(5):2169-78
pubmed: 27347324
Cell Death Differ. 2018 Aug;25(8):1364-1374
pubmed: 29348675
BMJ Open. 2018 Mar 1;8(3):e015187
pubmed: 29500198
J Bone Miner Res. 2000 Nov;15(11):2178-86
pubmed: 11092398
Blood. 2005 Aug 1;106(3):852-9
pubmed: 15817678
Clin Microbiol Rev. 2017 Jul;30(3):811-825
pubmed: 28539504
Leukemia. 2011 Dec;25(12):1891-9
pubmed: 21788946
Mol Cells. 2014 Sep;37(9):685-90
pubmed: 25220258
Cell Prolif. 2018 Oct;51(5):e12470
pubmed: 30117209
J Bone Miner Res. 2020 Jan;35(1):196-210
pubmed: 31610061
Int J Biol Sci. 2015 Aug 15;11(10):1204-14
pubmed: 26327814
J Exp Bot. 2009;60(11):3221-38
pubmed: 19592501
Theranostics. 2019 Feb 28;9(6):1634-1650
pubmed: 31037128
Theranostics. 2019 Jul 3;9(16):4648-4662
pubmed: 31367247
In Vivo. 2019 May-Jun;33(3):811-814
pubmed: 31028201
Am J Transl Res. 2019 Jun 15;11(6):3328-3340
pubmed: 31312347
Cell Death Differ. 2014 Oct;21(10):1613-21
pubmed: 24902903
Microbiologyopen. 2019 Aug;8(8):e00810
pubmed: 31001921
J Bone Miner Res. 2010 Apr;25(4):819-29
pubmed: 19821778
Oxid Med Cell Longev. 2020 Mar 12;2020:6983268
pubmed: 32256958